

Akums Drugs bags DCGI, CDSCO approval for Bempedoic acid tabs

25 May 2022 | News

Bempedoic Acid is a novel, non-statin, orally taken lipid-lowering treatment option indicative of being low risk for patients with intolerability for statins, an important ingredient in lipid-lowering drugs



Akums Drugs & Pharmaceuticals has acquired the license to manufacture and commercialise the drug named Bempedoic acid from DCGI and CDSCO. Bempedoic acid is a new class of drug for treating high LDL-cholesterol conditions that are indicative of cardiovascular diseases.

Sandeep Jain, Founder, Promoter and Director, Akums Drugs & Pharmaceuticals, says "Our research & development teams are working on various combinations of Bempedoic plus other molecules and soon these innovative products will also be introduced in India".

Sanjeev Jain, Founder, Promoter and Director, Akums Drugs & Pharmaceuticals, says "This therapy is an important addition to the management of dyslipidaemia through effective disease management. We will capture significant market share and be the pioneers in introducing the complete range of Bempedoic acid."